# NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3a377d4b
Ticker: NAMS
Company: NewAmsterdam Pharma
Source: NewAmsterdam Pharma
Published: 2026-07-02 20:01 EST
Original Source URL: https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-18
## Summary

NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

## Article Body
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 28,700 of NewAmsterdam’s ordinary shares to four non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $35.17, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on July 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 8,100 of NewAmsterdam’s ordinary shares to four non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units were granted on July 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.

About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact Matthew Philippe P: 1-917-882-7512 [email protected]
## Recent Company News
- 2026-07-02 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3a377d4b) — Source: NewAmsterdam Pharma
- 2026-07-01 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-associat-5f8e7eb9) — Source: NewAmsterdam Pharma
- 2026-06-25 13:46 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-national-lipid-association-nla-2026-scientific-sessions) — Source: NewAmsterdam Pharma
- 2026-06-25 13:46 EST — [NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june) — Source: NewAmsterdam Pharma
- 2026-06-25 13:46 EST — [NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-may) — Source: NewAmsterdam Pharma
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)